Healthcare -
Biotechnology - NASDAQ - US
$ 0.789
3 %
$ 22.1 M
Market Cap
-0.38
P/E
1. INTRINSIC VALUE
Balance Sheet
NextCure, Inc.
| Current Assets | 113 M |
| Cash & Short-Term Investments | 108 M |
| Receivables | 0 |
| Other Current Assets | 4.43 M |
| Non-Current Assets | 15.3 M |
| Long-Term Investments | 0 |
| PP&E | 13.4 M |
| Other Non-Current Assets | 1.88 M |
| Current Liabilities | 6.88 M |
| Accounts Payable | 2.33 M |
| Short-Term Debt | 656 K |
| Other Current Liabilities | 3.9 M |
| Non-Current Liabilities | 6.73 M |
| Long-Term Debt | 5.95 M |
| Other Non-Current Liabilities | 785 K |
EFFICIENCY
Earnings Waterfall
NextCure, Inc.
| Revenue | 0 |
| Cost Of Revenue | 3.68 M |
| Gross Profit | -3.68 M |
| Operating Expenses | 67.6 M |
| Operating Income | -67.6 M |
| Other Expenses | -4.91 M |
| Net Income | -62.7 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
NextCure, Inc.
| Net Income | -62.7 M |
| Depreciation & Amortization | 3.68 M |
| Capital Expenditures | -820 K |
| Stock-Based Compensation | 8.19 M |
| Change in Working Capital | -1.94 M |
| Others | -183 K |
| Free Cash Flow | -53.8 M |
Wall Street Analysts Price Targets
NextCure, Inc.
Wall Street analysts predict an average 1-year price target for NXTC of $3 , with forecasts ranging from
a
low of
$3 to a high of $3 .
NXTC Lowest Price Target
Wall Street Target
3 USD
280.23%
NXTC Average Price Target
Wall Street Target
3 USD
280.23%
NXTC Highest Price Target
Wall Street Target
3 USD
280.23%
4. DIVIDEND
ANALYSIS
NXTC does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
NextCure, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
5 years ago
Nov 15, 2019
|
Bought
5.51 M USD
|
Sofinnova Venture Partners IX, L.P.
10 percent owner
|
+ 150000
|
36.75 USD |
|
5 years ago
May 13, 2019
|
Bought
6 M USD
|
Sofinnova Venture Partners IX, L.P.
10 percent owner
|
+ 400000
|
15 USD |
|
5 years ago
May 13, 2019
|
Bought
750 K USD
|
SHANNON TIMOTHY M
Director
|
+ 50000
|
15 USD |
|
5 years ago
May 13, 2019
|
Bought
5.25 M USD
|
Khuong Chau Quang
Director
|
+ 350000
|
15 USD |
|
5 years ago
May 13, 2019
|
Bought
1.88 M USD
|
Xu Stella
Director
|
+ 125000
|
15 USD |
|
5 years ago
May 13, 2019
|
Bought
750 K USD
|
CANAAN X L.P.
10 percent owner
|
+ 50000
|
15 USD |
|
5 years ago
May 13, 2019
|
Bought
5.25 M USD
|
ORBIMED ADVISORS LLC
director, 10 percent owner:
|
+ 350000
|
15 USD |
7. News
NextCure Announces Acceptance of IND Application for LNCB74
LNCB74 is a B7-H4-targeting antibody-drug conjugate being developed for multiple cancers in partnership with LigaChem Biosciences LNCB74 is a B7-H4-targeting antibody-drug conjugate being developed for multiple cancers in partnership with LigaChem Biosciences
globenewswire.com
- 1 month ago
NextCure to Participate in the 36th Annual Piper Sandler Healthcare Conference
BELTSVILLE, Md., Nov. 26, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that it will participate in a fireside chat at the 36th Annual Piper Sandler Healthcare Conference in New York City on Thursday, December 5, at 12:00 pm ET.
globenewswire.com
- 1 month ago
Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis Imperfecta
BELTSVILLE, Md., Nov. 19, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced the presentation of preclinical data demonstrating that treatment with NC605, a novel anti-Siglec-15 (S15) antibody, resulted in enhanced generation of quality bone with better mechanical properties, in an oral presentation at the Osteogenesis Imperfecta Federation Europe virtual Investigator Meeting on November 15th, 2024. These results demonstrate that NC605 is a highly effective treatment for Osteogenesis Imperfecta (OI), also known as brittle bone disease in a well-established model of disease.
globenewswire.com
- 2 months ago
NextCure Provides Business Update and Reports Third Quarter 2024 Financial Results
BELTSVILLE, Md., Nov. 07, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today provided a business update and reported third-quarter 2024 financial results.
globenewswire.com
- 2 months ago
NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual Meeting
BELTSVILLE, Md., Nov. 05, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today reports pre-clinical data from LNCB74, a B7-H4-targeting antibody-drug conjugate (ADC) being developed in partnership with LigaChem Biosciences (LCB) (KOSDAQ: 141080), and biomarker data from the NC410 combination study with pembrolizumab in patients with immune checkpoint inhibitor (ICI) naïve and refractory microsatellite stable (MSS)/microsatellite instability-low (MSI-L) colorectal cancer (CRC). The data will be presented during poster sessions at the Society for Immunotherapy of Cancer (SITC) annual meeting.
globenewswire.com
- 2 months ago
NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting
BELTSVILLE, Md., Oct. 04, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced two presentations at the Society for Immunotherapy of Cancer (SITC) annual meeting, to be held in Houston, TX from November 6-10, 2024. NextCure will share pre-clinical data from LNCB74 (B7-H4 ADC) and biomarker data from NC410 combination study with pembrolizumab in ICI-naïve MSS/MSI-L CRC during poster sessions.
globenewswire.com
- 3 months ago
NextCure Presented Results of the Phase 1b Study of NC410 in Combination with Pembrolizumab at ESMO 2024
BELTSVILLE, Md., Sept. 16, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that clinical data from the Phase 1b portion of a Phase 1b/2 study evaluating NC410, a LAIR-2 fusion protein, in combination with pembrolizumab was presented at ESMO 2024. The trial, which is evaluating the combination in ovarian cancer and immune checkpoint inhibitor (ICI) naïve and refractory microsatellite stable (MSS)/microsatellite instability-low (MSI-L) colorectal cancer (CRC), demonstrated clinical activity in these hard-to-treat cancers. The data were presented by clinical trial investigators Emese Zsiros, M.D., Ph.D., Associate Professor of Oncology, Chair, Department of Gynecologic Oncology, Roswell Park Comprehensive Cancer Center (ovarian) and Eric S. Christenson, M.D., Assistant Professor of Oncology at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center (CRC). The presentations are available on the NextCure website (www.nextcure.com).
globenewswire.com
- 4 months ago
NextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
BELTSVILLE, Md., June 20, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies, today announced that it will present and host institutional investor meetings at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference on Thursday, June 27, 2024.
globenewswire.com
- 6 months ago
NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024
BELTSVILLE, Md., May 30, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that clinical data from the Phase 1b portion of a Phase 1b/2 study evaluating NC410, a LAIR-2 fusion protein, in combination with pembrolizumab will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The trial evaluated the combination in immune checkpoint inhibitor (ICI) naïve and refractory microsatellite stable (MSS)/microsatellite instability-low (MSI-L) colorectal cancer (CRC) and ovarian cancer and demonstrated clinical activity in these hard-to-treat cancers. The data will be presented in a poster session by clinical trial investigator Eric S. Christenson, M.D., Assistant Professor of Oncology at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center.
globenewswire.com
- 7 months ago
NextCure Provides Business Update and Reports First Quarter 2024 Financial Results
BELTSVILLE, Md., May 02, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today provided a business update and reported its first-quarter 2024 financial results.
globenewswire.com
- 8 months ago
NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024
BELTSVILLE, Md., April 24, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that clinical trial investigator Eric S.
globenewswire.com
- 8 months ago
NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024
Poster presentation highlights strong safety and pharmacokinetic profiles for LNCB74 Poster presentation highlights strong safety and pharmacokinetic profiles for LNCB74
globenewswire.com
- 9 months ago
8. Profile
Summary
NextCure, Inc. NXTC
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 22.1 M
Dividend Yield
0.00%
Description
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4; and NC525, a novel LAIR-1 antibody which is in Preclinical trails that targets acute myeloid leukemia, blast cells, and leukemic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.
Contact
9000 Virginia Manor Road, Beltsville, MD, 20705
https://www.nextcure.com
IPO
Date
May 9, 2019
Employees
82
Officers
Dr. Lieping Chen M.D., Ph.D.
Co-Founder & Chairman of Scientific Advisory Board
Mr. Steven P. Cobourn CPA
Chief Financial Officer
Dr. Sebastien Maloveste Ph.D.
Senior Vice President of Business Development
Mr. Sourav Kundu Ph.D.
Senior Vice President of Development & Manufacturing
Mr. Michael S. Richman MSBA
Co-Founder, Chief Executive Officer, President & Director
Dr. Timothy Mayer Ph.D.
Chief Operating Officer
Mr. Kevin G. Shaw
Senior Vice President & General Counsel
Dr. Udayan Guha M.D., Ph.D.
Senior Vice President of Clinical & Translational Development
Dr. Solomon Langermann Ph.D.
Chief Scientific Officer